Analysts positive on US prospects for tivozanib but data request weighs on Aveo stock
This article was originally published in Scrip
Executive Summary
It's hard to say whether investors were reacting more to Aveo Oncology's larger net loss or news that the US FDA had asked for more data on overall survival rates versus Nexavar (sorafenib) for the US company's Phase III kidney cancer drug and lead product candidate tivozanib, but the firm's stock price fell 26.8% when it announced second quarter 2012 earnings on 2 August.